Scilex Holding Company Common Stock earnings per share and revenue
On Nov 14, 2025, SCLX reported earnings of -- USD per share (EPS) for Q3 25, -- the estimate of -0.83 USD, resulting in a --% surprise. Revenue reached 10.56 million, compared to an expected 26.77 million, with a -60.56% difference. The market reacted with a -12.32% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.96 USD, with revenue projected to reach 12.34 million USD, implying an -- of --% EPS, and increase of 16.87% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Scilex Holding Company Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Scilex Holding Company Common Stock reported EPS of --, missing estimates by --, and revenue of $10.56M, -60.56% below expectations.
How did the market react to Scilex Holding Company Common Stock's Q3 2025 earnings?
The stock price moved down -12.32%, changed from $17.69 before the earnings release to $15.51 the day after.
When is Scilex Holding Company Common Stock expected to report next?
The next earning report is scheduled for Mar 30, 2026.
What are the forecasts for Scilex Holding Company Common Stock's next earnings report?
Based on 3
analysts, Scilex Holding Company Common Stock is expected to report EPS of -$0.96 and revenue of $12.34M for Q4 2025.